Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Andy, Sykes"'
Autor:
Nicholas Turner, Christos Vaklavas, Emiliano Calvo, Javier Garcia-Corbacho, Jason Incorvati, Manuel Ruiz Borrego, Chris Twelves, Anne Armstrong, Begoña Bermejo, Erika Hamilton, Mafalda Oliveira, Eva Ciruelos, Peter Kabos, Manish R Patel, Maria Borrell, Howard Burris, Bruno de Paula, Alejandro Falcon, Cristina Hernando, Irene Moreno, Ciara S. O’Brien, Elena Shagisultanova, Ivan Victoria Ruiz, Judy S. Wang, Mei Wei, Tim Brier, Danielle Carroll, Carmela Ciardullo, Lisa Gibbons, itziar irurzun-Arana, Tony Jack, bistra kirova, Teresa Klinowska, Justin Lindemann, Julie Maidment, Alastair Mathewson, Rhiannon Maudsley, Robert McEwen, Christopher Morrow, Andy Sykes, Richard D. Baird
Background: SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in women with ER+/HER2− advanced breast cancer. Parts A/B and C/D (escalation/expansion) examined camizestrant as monotherapy and in combination with palb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3b0f1e0fcbdd82a029a528d47540d2
https://www.repository.cam.ac.uk/handle/1810/350214
https://www.repository.cam.ac.uk/handle/1810/350214
Autor:
Andy Sykes, Nadine Stech, Piotr Laszczak, Michael McGrath, Alan Kercher, Saeed Zahedi, David Moser
Publikováno v:
Canadian Prosthetics & Orthotics Journal (2018)
INTRODUCTION For many years, the biomechanical evaluation of prosthetic performance has centred around gait analysis and motion capture. While this provides useful, scientific insights, everyday life is not limited to straight-line, level, steady
Externí odkaz:
https://doaj.org/article/0c94d035663b4c40916bcd3c889cf62e
Autor:
Filip Miljković, Andreas Bender, Beth Williamson, Andy Sykes, Martin Johnson, Anton Martinsson, Nigel Greene, Olga Obrezanova
Publikováno v:
Molecular Pharmaceutics. 18:4520-4530
Prior to clinical development, a comprehensive pharmacokinetic characterization of a novel drug is required to understand its exposure at the site of action and elimination. Accordingly, in vitro assays and animal pharmacokinetic studies are regularl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54447022988786738bcf709d604f55da
https://doi.org/10.1021/acs.molpharmaceut.1c00718
https://doi.org/10.1021/acs.molpharmaceut.1c00718
Autor:
Andy Sykes, Christopher J. Morrow, Richard D. Baird, Teresa Klinowska, Rhiannon Maudsley, Marta Capelán Rodríguez, Manuel Ruiz-Borrego, Tim Brier, Bistra Kirova, Justin P.O. Lindemann, Nitharsan Sathiyayogan, Christina Hernando, Julia Lai-Kwon, Javier Garcia-Corbacho, Judy S. Wang, Begoña Bermejo de las Heras, Steven Fox, Mafalda Oliveira, Chris Leach, Eva Maria Ciruelos Gil, Anne C Armstrong, Richard Mather, Erika Hamilton, Manish R. Patel, Jason Incorvati, Udai Banerji, Valentina Boni, Chris Twelves, Ivan Victoria Ruiz, Bruno de Paula, Alejandro González, Li Zhang, Anosheh Afghani, Peter Kabos, Christos Vaklavas, Adam L. Cohen
Publikováno v:
Cancer Research. 81:PS11-05
Background: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader (SERD) in Phase 2 clinical development for the treatment of ER+ HER2− breast cancer. Here we report data from Parts C and D of the ongoing Phase 1 study (SERENA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a72b8540deb1a95e3a1f45931a47ee6e
https://doi.org/10.1158/1538-7445.sabcs20-ps11-05
https://doi.org/10.1158/1538-7445.sabcs20-ps11-05
Autor:
Per Stenkrona, Zsolt Cselényi, Martin Pass, Mohammad Mahdi Moein, Andrea Varrone, Andy Sykes, Lars Farde, Christer Halldin, Chris Davison, Serena De Vita, Venkatesh Pilla Reddy, Núria Buil-Bruna, Melinda S. Merchant, Alicia Savage, Katarina Varnäs, Matthias Hoch, Magnus Schou, Peter Johnström, Aurelija Jucaite, Ana Vazquez-Romero
Publikováno v:
Neuro Oncol
Background The protein kinase ataxia telangiectasia mutated (ATM) mediates cellular response to DNA damage induced by radiation. ATM inhibition decreases DNA damage repair in tumor cells and affects tumor growth. AZD1390 is a novel, highly potent, se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbfb688a1e94c6c9ad2d65bea16ed066
https://pubmed.ncbi.nlm.nih.gov/33704490
https://pubmed.ncbi.nlm.nih.gov/33704490
Autor:
Sho Sato, Andy Sykes, Stuart Stafford, Yoshihiko Tagawa, Rosa Fradley, Shyam Bechar, Eimear Howley, Tomoki Yoneyama, Toshal Patel, Toshiya Moriwaki, Satoru Asahi
Publikováno v:
Pharmaceutical Research
Purpose TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::555d0fce1c6fb48f63df6e77a80c4bce
https://doi.org/10.1007/s11095-020-02893-x
https://doi.org/10.1007/s11095-020-02893-x
Autor:
Michael Davies, Scott W. Martin, Tashinga E. Bapiro, Helen Rollison, James W.T. Yates, Andy Sykes, Matthias Hoch, Barry Jones
Publikováno v:
Drug Metabolism and Disposition. 46:1268-1276
AZD9496 ((E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid) is an oral selective estrogen receptor degrader currently in clinical development for treatment of estroge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64630c2477542c1fe35d686fa058554b
https://doi.org/10.1124/dmd.118.081539
https://doi.org/10.1124/dmd.118.081539
Autor:
Kengo Okada, Toshal Patel, William Farnaby, Helen Harrison, Natasha Kinsella, Kevin John Merchant, Michael Bestwick, Jonathan Ellery, Louise Marie Walsh, Hannah E. Canning, Mathew Leveridge, Phillip Mitchell, Charlotte Fieldhouse, Andy Sykes, Isaac Hoffman, Miller David, Rosa Fradley, Eimear Howley, Katherine Hazel, Kerr Catrina, Livermore David, Matt Barnes, Mark B. L. Carlton
Publikováno v:
Neurochemical Research. 42:3279-3288
Irregular N-methyl-D-aspartate receptor (NMDAR) function is one of the main hypotheses employed to facilitate understanding of the underlying disease state of schizophrenia. Although direct agonism of the NMDAR has not yielded promising therapeutics,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28004329f3c6dc8f4c521182e1e00549
https://doi.org/10.1007/s11064-017-2367-9
https://doi.org/10.1007/s11064-017-2367-9
Autor:
Andy Sykes, Richard Mather, Teresa Klinowska, Christopher J. Morrow, John F.R. Robertson, Joanna Harding, Alastair Mathewson, Li Zhang, Rhiannon Maudsley, Giorgi Dzagnidze, Andrew Saunders, Juan Enrique Bargallo Rocha, Iain K. Moppett, Justin P.O. Lindemann
Publikováno v:
Cancer Research. 81:OT-09
Background AZD9833 is an orally bioavailable selective estrogen receptor (ER) antagonist and degrader (SERD) that has shown anti-tumor efficacy in a range of preclinical breast cancer models. SERENA-1, an ongoing first-in-human study assessing AZD983
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f1ef461a12bc9b37df07c3b5a5f5123
https://doi.org/10.1158/1538-7445.sabcs20-ot-09-05
https://doi.org/10.1158/1538-7445.sabcs20-ot-09-05